Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06147388

Regression of Cervical Precancerous Lesions and Associated Risk Factors

The aim of this study is to assess the extent of histopathological regression of severe cervical precancerous lesions (CIN 2 and CIN 3); evaluate the proportion of patients who experience the normalization of HPV test and cytology finding among those who were treated conservatively and those who underwent conization; and identify predictive parameters associated with regression. Based on this analysis, a model will be proposed to predict the likelihood of lesion regression.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–40 year

Sex eligibility

Female

Study type

Observational

Primary location

About this study

Introduction There are three grades of dysplasia of the cervix based on their severity (CIN 1-3). Most women with CIN 2 or CIN 3 (high-grade - HG lesions) are referred for conization due to the presumed risk of developing invasive cervical cancer. However, this surgical intervention is associated with an increased risk of preterm labor in the future.

From the literature, it is evident that 30% - 60% of CIN 2 and CIN 3 lesions spontaneously regress. Colposcopic examination is a tool that can accurately assess the severity of the lesion and safely evaluate the dynamics of its development. It can be used to exclude the presence of invasive cervical cancer.

The aim of the study is to determine the absolute rate of spontaneous regression of HG lesions, considering stratification factors.

Methods Patients meeting all inclusion criteria and none of the exclusion criteria are included (see below). Colposcopic evaluations occur at four-month intervals during the study. In case of progression, the patient is indicated for conization; in case of persistence, the patient is consulted and can choose further observation or conization; in case of regression, punch biopsy is performed to acquire a histopathologic sample for primary endpoint evaluation. The biopsy/conization result is subsequently compared with the initial sample to declare regression or persistence of the HG lesion.

The HPV status and cytological findings are evaluated similarly. Stratification criteria such as age, colposcopic characteristics, HPV genotype (Cobas 4800, Roche Molecular Systems, Pleasanton, USA), methylation markers (GynTect®, Oncgnostics GmbH, Löbstedter Str. 41, 07749 Jena, Germany), semiquantitative microscopic assessment of the vaginal swab, and personal history are assessed during monitoring.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • squamocolumnar junction fully visualized
  • bioptically verified CIN 2 or CIN 3
  • age ≥ 18 years
  • age ≤ 40 years
  • informed consent

Exclusion criteria

  • squamocolumnar junction not fully visualized
  • suspicion on glandular lesion
  • suspicion on invasive cancer
  • personal history of CIN 2, 3 or cerv. cancer
  • gravidity
  • HIV positivity
  • immunosuppression
  • impossible photographic documentation

Treatment and study plan

Colposcopy

Diagnostic Test

No surgery, observation

Primary outcomes

  1. Regression-rate of severe cervical precancerous lesions (CIN 2 and CIN 3) expressed through a comparison of initial and final histology

    Time frame: 3 years

    Histological results from the initial visit will be compared with the biopsy obtained during the last visit (or the specimen from conization) to determine whether regression or persistence of the high-grade lesion has occurred.

Secondary outcomes

  1. Rate of HPV negativization in patients with spontaneous regression compared to patients with persistence after conization

    Time frame: 3 years

    The proportion of patients with a negative result on the HPV DNA test obtained during the final visit will be assessed.

  2. Rate of cytological normalization in patients with spontaneous regression compared to patients with persistence after conization

    Time frame: 3 years

  3. Regression-rate considering specified stratification factors

    Time frame: 3 years

    Specific factors will be evaluated to determine their influence on the regression or persistence of the cervical high-grade lesion. The following factors will be assessed:

    • CIN Grade (CIN 2 / CIN 3)
    • Immunohistochemically detected biomarkers
    • p16INK4a
    • Ki-67
    • E4
    • Gene methylation (ASTN1, DLX1, ITGA4, RXFP3, SOX17, and ZNF671)
    • Histologically described cervicitis
    • Colposcopic Markers
    • Microbiological Markers
    • Selective HPV genotyping
    • Viral load
    • Anamnestic Data
    • Smoking
    • Age
  4. Development of a model for predicting spontaneous regression

    Time frame: 3 years

Study contacts

Contact information is provided by the study sponsor or research team.

Lukas Dostalek

CONTACT

[email protected]

+420224967451

Sponsors and collaborators

Lead sponsor

General University Hospital, Prague

Other

Registry information

Acronym: RECER

Important dates

Study start
2022
Primary completion
2026
Study completion
2027
First posted
Nov 27, 2023
Registry last updated
Feb 25, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.